Mirum Pharmaceuticals, Inc.
MIRM
$43.42
-$0.03-0.07%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 46.18% | 39.21% | 38.08% | -22.74% | -20.45% |
| Total Depreciation and Amortization | 118.21% | 238.88% | 274.62% | 244.83% | 211.03% |
| Total Amortization of Deferred Charges | 48.70% | 128.97% | 431.27% | -- | -- |
| Total Other Non-Cash Items | -50.54% | -36.79% | -38.84% | 181.23% | 201.31% |
| Change in Net Operating Assets | 217.53% | 181.16% | 146.43% | 152.03% | 8.69% |
| Cash from Operations | 114.55% | 98.62% | 75.70% | 62.76% | 40.95% |
| Capital Expenditure | -811.01% | -177.21% | -114.05% | 74.61% | 60.79% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | 100.00% | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -184.35% | -168.16% | -274.63% | 5,462.55% | 1,224.53% |
| Cash from Investing | 15.93% | -18.26% | -1,138.65% | -7,419.78% | -1,492.21% |
| Total Debt Issued | -- | -100.00% | -100.00% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -92.21% | -93.64% | 102.68% | 90.32% | 98.15% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 99.86% | 99.86% | -2,413.35% | -3,427.70% |
| Cash from Financing | -94.74% | -95.77% | 1.86% | 212.42% | 208.56% |
| Foreign Exchange rate Adjustments | -875.19% | 221.79% | -254.35% | -202.46% | -1,208.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -140.04% | -147.62% | -144.90% | 4,775.25% | 4,844.47% |